ERBB2 and gastric cancer: The phase II DESTINY-Gastric01 trial (Shitara et al. 2020a) conducted in Japan and South Korea showed that in patients with HER2-positive GC who had progressed after two or more prior treatments including trastuzumab, the ORR was significantly higher in the T-DXd group than in the standard chemotherapy group (51% vs 14%, P < 0.001).